Effective August 2, 2022, mdxhealth has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences. To help ensure a smooth transition for patients, continue to place orders for this test through the existing Exact Sciences portal until further notice. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the Oncotype DX GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the following press release. Questions? Email: gps@mdxhealth.com

Jorge Garces

Jorge Garces

Chief Science Officer

Joined Exact Sciences: 2021

Jorge Garces has served as our Chief Science Officer since April 2021. He served as our Vice President, Minimal Residual Disease (MRD) and Therapy Selection from February 2021 to April 2021. Mr. Garces brings decades of experience in diagnostics including a focus on the development, clinical trials, and commercialization of liquid biopsy tests in the field of oncology. Prior to joining Exact Sciences, Mr. Garces served as President and Chief Scientific Officer at Epigenomics AG.  He also served as CEO and President of AltheaDx Inc., a clinical diagnostics company, and co-founder of IDGenetix, Inc., a precision medicine start-up acquired by AltheaDx in 2013. Mr. Garces also served as Chief Executive Officer and President of Enigma Diagnostics, where he executed commercial licensing, product development and supply agreement with GlaxoSmithKline around respiratory infectious disease screening. Earlier in his career, he held leadership positions at Hologic, Inc., Third Wave Technologies, Genzyme Genetics, and Athena Diagnostics. He earned his doctorate in Cell and Molecular Biology from the City University of New York, completed his post-doctoral training in neurobiology at the University of Massachusetts Medical School, and received an MBA from the Kellogg Graduate School of Management at Northwestern University.